Acazetina

Otros Nombres

2-(4-Methoxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one4'-Methoxyapigenin4'-Methylapigenin4'-O-Methylapigenin4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-methoxyphenyl)-5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one5,7-dihydroxy-4'-methoxy-flavone5,7-Dihydroxy-4'-methoxyflavone5,7-dioxi-4'-methoxyflavone7-O-MethylapigeninAcacetineAcacetinumApigenin 4'-methyl etherBuddleoflavonolLinarigeninLinariseninLY 064233Methyl-4'-apigeninNSC 76061

Sinopsis

Acacetin: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Names and Classification

Acacetin (5,7-dihydroxy-4′-methoxyflavone) is a flavonoid compound found in black locust (Robinia pseudoacacia). More precisely, acacetin is a 4′-O-methylated flavone of the parent compound apigenin. It is a di-hydroxy and mono-methoxy flavone, meaning it carries hydroxyl groups at positions 5 and 7 of the A-ring and a methoxy substituent at the 4′ position of the B-ring. Acacetin is a flavonoid that occurs naturally in plants as a glycoside with attached glucose, rhamnose, or glucuronic acid moieties. In its free, unconjugated form it is referred to as the aglycone; acacetin exists naturally in various plants in the form of an aglycone or a glycoside.

Flavonoids are a large class of phenolic compounds whose basic skeleton (C6-C3-C6) is composed of a benzene ring A attached to a pyrone ring C and a phenyl ring B at position 2 or 3. They can be generally classified into seven distinct subtypes according to their structural differences: chalcones, isoflavones, flavones, flavanols, anthocyanidins, flavanones, and flavonols. Acacetin belongs specifically to the flavone subclass.

A PubMed search conducted in August 2025 retrieved 7,966 publications for luteolin and 7,570 for apigenin — two flavonoids structurally related to acacetin — but only 715 for acacetin, indicating that acacetin has been investigated at roughly one-tenth the level of these well-established flavonoids. Despite this relative gap in the literature, research output has accelerated notably since the early 2000s.

Botanical Sources

Acacetin has been isolated from black locust (Robinia pseudoacacia), bee propolis, Dracocephalum moldavica, Turnera diffusa, and Betula pendula, as evidenced by chemical profiling in peer-reviewed studies. These sources include widely used foods or ethnomedicinal plants. The molecule is widespread throughout the plant kingdom but is particularly abundant in the Asteraceae, Euphorbiaceae, Passifloraceae, Lamiaceae, and Malvaceae families.

Acacetin (5,7-dihydroxy-4′-methoxyflavone) is the major bioactive component of the traditional Chinese medicine "Snow lotus." As a natural flavonoid compound, it has been shown to have good pharmacological activity. Specifically, the well-known Tianshan snow lotus (Saussurea involucrata), which belongs to the eudicot family Asteraceae, is a famous traditional Chinese medicinal herb having anti-inflammatory, antioxidant, and anti-cancer effects; the major bioactive components that exhibit clinical functions in this plant are acacetin, hispidulin, and rutin.

Robinia pseudoacacia, Chrysanthemum indicum, and other species are also recognized botanical sources. Damiana (Turnera diffusa) contains acacetin alongside damianin, tetraphyllin B, gonzalitosin I, arbutin, p-cymene, β-sitosterol, apigenin, thymol, tannins, and other constituents. Notably, acacetin was identified as a compound present exclusively in acacia honey samples collected in Romania, making it a useful chemical marker for authenticating this specific honey type.

Biosynthesis and Production

By integrating flavonoid synthase and 4′-O-methyltransferase genes, efficient biosynthesis of acacetin from naringenin was achieved. Under fed-batch fermentation conditions with optimized carbon-to-nitrogen ratio, the production of acacetin reached 1.10 g/L. However, the extraction of acacetin from plants faces bottlenecks such as slow growth and complex purification processes, making heterologous biosynthesis essential for its efficient production. The Baker–Venkataraman rearrangement is a commonly utilized method for constructing acacetin chemically.

Common Forms and Preparations

Acacetin is encountered in research and commercial settings as a purified aglycone powder (typically ≥98% purity), as standardized plant extracts (particularly from Saussurea involucrata, Robinia pseudoacacia, and Turnera diffusa), and as its naturally occurring glycosides. Toxicity, safety, related patents, and commercial products have been discussed in the literature, but show limited information. A water-soluble prodrug form of acacetin has also been developed and studied in preclinical cardiovascular research to address the compound's inherent solubility limitations, described in detail in the pharmacokinetics section below.

2. Traditional and Historical Use

Traditional Chinese Medicine and Traditional Uyghur Medicine

Saussureae Involucratae Herba is the dried ground part of Saussurea involucrata, also named "Snow lotus," used in traditional Uyghur and/or Chinese medicine. This rare herb can be found at 4,000 m elevation in the western part of Tianshan Mountain, Xinjiang, China. According to the China Pharmacopoeia (2015), the major pharmaceutical values of "Snow lotus" (Xuě liánhuā in Chinese) are alleviating rheumatoid arthritis, accelerating blood circulation, and mitigating other "cold" syndromes. Traditionally, the clinical application of "Snow lotus" includes treatments for inflammation-associated disorders, blood circulation acceleration, and heat and dampness elimination.

The history of Traditional Uyghur Medicine (TUM) spans over 2,500 years and is still being practiced today. Ghazi Bay recorded fennel, senna, salt, and 312 types of TUM herbs, as well as their therapeutic functions, in the book of "Ghazi Bay medicinal book," written around 400 B.C.

In traditional Chinese medicine, S. involucrata has long been used to enhance blood circulation, expelling wind, eliminating heat and dampness, and is also used to improve stomachache and menstrual disorders. This materia medica is one of the major ingredients found within "Snow lotus" capsules sold in China, aimed at dysmenorrhea treatment. A water decoction combining "Snow lotus," Lycii fructus, and Angelica sinensis Radix was used to promote the secretion of androgen, to enhance sexual function in male patients, and for infertility treatment.

Mesoamerican and Central American Traditions

Damiana (Turnera diffusa) is traditionally used in Mexican liqueurs and margaritas, was historically featured in 19th-century patent medicines as an alleged aphrodisiac, and today is valued in herbal teas and smoking blends for its calming and mild psychoactive effects. It contains a complex mix of phytochemicals including flavonoids like apigenin and acacetin, terpenoids, phenolics, cyanogenic glycosides, and others. Acacetin is thus one constituent among many in damiana, and the traditional uses of the plant as a whole cannot be attributed specifically to acacetin without further research.

Contextual Note on Traditional Attribution

It is important to note that in traditional medicinal systems, plant preparations were used as whole extracts or decoctions, not as purified single compounds. The isolation and identification of acacetin as a specific chemical entity is a product of modern analytical chemistry. As of 2006, damiana's constituents have not been identified for their individual effects attributed to the whole herb. Similarly, recent studies have suggested that "Snow lotus" possesses therapeutic effects associated with anti-cancer, anti-oxidation, adipogenesis suppression, and neuroprotection activities, which were proposed to be related with its bioactive constituents acacetin, hispidulin, and rutin — meaning the attribution of these effects to acacetin specifically is a matter of ongoing scientific investigation, not established traditional knowledge.

3. Key Constituents, Chemical Properties, and Mechanisms of Action

Structural Properties

Acacetin (5,7-dihydroxy-4-methoxyflavone) is a naturally occurring flavonoid, known to possess numerous pharmacological properties, including neuroprotective, cardioprotective, anticancer, anti-inflammatory, antidiabetic, and antimicrobial activities. Its structural distinction from the parent compound apigenin is the 4′-methoxylation of the B-ring, which modifies its receptor-binding profile and metabolic fate relative to apigenin. Acacetin exerts a potent endothelium-independent vaso-relaxing effect, which has been attributed to the hydroxyl group at position 5, and this finding suggests a possible interaction with large-conductance, calcium-activated potassium channels.

Major Enzyme Targets and Signaling Pathways

Acacetin has been shown to exhibit strong inhibitory effects against glutathione reductase, cyclo-oxygenase (COX), acetylcholinesterase, aldose reductase, and xanthine oxidase enzymes.

Acacetin has demonstrated diverse pharmacological actions, including anticancer, anti-inflammatory, antioxidant, and hepatoprotective effects through modulation of key intracellular pathways such as MAPK/c-Jun N-terminal kinase (JNK)/ERK, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), PI3K/AKT/mTOR, and cyclooxygenase (COX)-2.

The underlying mechanisms by which acacetin exhibits cardiovascular protection appear to involve suppressing oxidative stress, reducing inflammation, preventing cardiomyocyte apoptosis and endothelial cell injury, as well as regulating mitochondrial autophagy and lipid metabolism.

Anti-inflammatory Mechanisms

Acacetin has been shown to prevent inflammation in several studies, thus delaying or improving many diseases, such as sepsis-induced acute lung injury, ulcerative colitis, pancreatic and hepatorenal dysfunction associated with type 2 diabetes, and Parkinson's disease. In an animal model of cerebral ischemia/reperfusion injury, acacetin could decrease the release of pro-inflammatory cytokines like tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1β, through regulating the TLR-4/NF-κB/NLRP3 signaling axis, demonstrating a neuroprotective role. Acacetin has also been shown to alleviate inflammation by preventing NLRP3 inflammasome activation through the modulation of signal molecules such as NF-κB p65, p38 MAPK, ERK, and JNK in mouse bone marrow-derived macrophages.

Anticancer Mechanisms

Acacetin has demonstrated anti-cancer potential in many cancer cell lines, which may be closely related to its antiproliferative and anti-invasive effects mediated by the activation of the NF-κB and MAPK pathways and the phosphorylation of Akt. Acacetin caused the decline in mitochondrial membrane potential, promoted the release of cytochrome c from mitochondria, and induced cell apoptosis in a variety of tumor cells, which was closely correlated with the MAPK-mediated signaling pathway. The inactivation of the PI3K/Akt/mTOR/p70S6K/ULK cascade was found to be crucial in acacetin-induced autophagy, cell cycle arrest, and apoptosis in human breast cancer cells.

Acacetin disrupts cell cycle progression in several cancer types, inducing G1 arrest in hepatocellular carcinoma via p53 and p21 upregulation, and S-phase arrest in colorectal carcinoma through the downregulation of cyclin A and cyclin-dependent kinase 2 (CDK2). These cell cycle regulatory effects are often accompanied by the inhibition of key pro-survival signaling pathways, including PI3K/AKT, MAPK/ERK, and STAT3, which are commonly dysregulated in malignant cells.

Antioxidant Mechanisms

An in vitro study demonstrated that acacetin could effectively attenuate xanthine oxidase (IC₅₀ 11.92 μM). Inhibition of the enzyme was proposed as a mechanism for improving cardiovascular activity. The Nrf2 pathway activation is a documented mechanism by which acacetin elevates endogenous antioxidant defenses; in cultured primary cardiomyocytes and H9C2 cells, acacetin reduced hypoxia/reoxygenation-evoked cell injury by blocking oxidative stress, apoptosis, and inflammation via the upregulation of AMPK/Nrf2 signaling.

Aromatase Modulation

A review of the literature revealed that acacetin has a modulating effect on the concentrations of various enzymes such as aromatase, which is responsible for converting testosterone to estrogen. This property has attracted interest in the context of hormonal regulation, though the clinical relevance in humans has not been established.

4. Scientific Evidence by Area of Use

4.1 Cardiovascular Disease

Atrial Fibrillation

The development of atrium-selective antiarrhythmic agents is a current strategy for inhibiting atrial fibrillation (AF). One key study investigated whether the natural flavone acacetin from the traditional Chinese medicine Xuelianhua would be an atrium-selective anti-AF agent. The effects of acacetin on human atrial ultrarapid delayed rectifier K⁺ current (I_Kur) and other cardiac ionic currents were studied with a whole-cell patch technique. Acacetin suppressed I_Kur and the transient outward K⁺ current (IC₅₀ 3.2 and 9.2 μmol/L, respectively) and prolonged action potential duration in human atrial myocytes. This study demonstrated that the natural compound acacetin is an atrium-selective agent that prolongs the atrial effective refractory period without prolonging the corrected QT interval and effectively prevents AF in anesthetized dogs after intraduodenal administration, indicating that oral acacetin is a promising atrium-selective agent for the treatment of AF.

This study was published in Circulation (American Heart Association) in 2008 and used in vitro human atrial myocyte electrophysiology combined with in vivo canine models. Evidence strength: preclinical only; no human clinical trials have been reported. Several studies have demonstrated that acacetin has potential anti-AF effects, but these results are based only on in vitro and animal models and require further clinical validation.

Ischemia/Reperfusion Injury

Recent studies have shown acacetin's efficacy in various cardiac diseases, including atrial fibrillation, myocardial infarction, and diabetic cardiomyopathy. In terms of ischemia/reperfusion (I/R) injury, preclinical data demonstrate cardioprotective effects via the Nrf2/HO-1 pathway. Evidence is limited to animal models and cell culture; no human trials have been conducted.

Diabetic Cardiomyopathy

To explore the role of acacetin in diabetic cardiomyopathy, researchers used high glucose-treated cardiomyocytes and STZ-induced diabetic cardiomyopathy rats as in vitro and in vivo models. They found that in vitro, acacetin (3 μM) markedly prevented the elevation of Bax protein and the decrease of antioxidant proteins SODs induced by high glucose. In vivo, acacetin prodrug (10 mg/kg) obviously ameliorated cardiac dysfunction and ventricular fibrosis and inhibited the elevation of serum MDA and IL-6.

Atherosclerosis and Endothelial Protection

The natural flavone acacetin, in addition to its atrial-selective anti-atrial fibrillation property, is cardioprotective against ischemia/reperfusion or hypoxia/reoxygenation injury and doxorubicin cardiotoxicity by its anti-oxidation, anti-inflammation, and anti-apoptosis properties. Studies from other research teams have demonstrated that acacetin has anticancer and anti-peroxidation and anti-neuronal inflammation properties.

Overall Cardiovascular Evidence Assessment

Increasing numbers of studies (mostly preclinical) have indicated that acacetin has potential cardiovascular protective effects and might become a novel therapeutic strategy for CVDs. However, the protective effects of acacetin against CVD rely mainly on data derived from existing animal models and in vitro experiments, and it is unclear whether acacetin still possesses cardiovascular protective effects in humans. Clinical studies are required to validate these preclinical findings. Overall, there is still a great distance to the routine clinical application of acacetin.

4.2 Oncology (Anticancer Activity)

In vitro and in vivo studies using diverse tumor models have demonstrated that acacetin modulates oncogenic signaling, suppresses angiogenesis, and induces apoptosis and other regulated cell death pathways.

Hepatocellular Carcinoma: Hsu et al. (2004) showed in HepG2 cells that acacetin inhibited cell growth, induced cell cycle arrest at G1 phase, and apoptosis through increased levels of p53 protein.

Non-Small Cell Lung Cancer: Acacetin could inhibit the invasion and migration of cancer cells via regulating the PI3K/Akt/Snail pathway. In vitro, acacetin inhibited the proliferation, invasion, and migration of NSCLC cells (A549 and H460) in a dose-dependent manner; flow cytometry results showed that acacetin induced G2/M phase cell cycle arrest and apoptosis of NSCLC cells.

Gastric Cancer: Acacetin played an anticancer role in gastric cancer by regulating the STAT3 and ERK pathways. Separately, in TGF-β1-induced epithelial-mesenchymal transition (EMT) models of gastric cancer cells, acacetin reversed the morphology of mesenchymal-like spindle-shaped cells and reduced invasion and migration stimulated by TGF-β1. Acacetin attenuated the overexpression of mesenchymal marker N-cadherin, transcription factor Snail, MMP2, and MMP9, while promoting the expression of epithelial marker E-cadherin. These results indicated that acacetin inhibited EMT and repressed invasion and migration in TGF-β1-treated gastric cancer cells.

Breast Cancer: Acacetin exhibits potent anticancer effects in T-47D and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest, generating ROS, and causing DNA damage that triggers RIP1-dependent necroptotic cell death. This activity is mediated by sustained ERK1/2 activation driven by ROS production. Acacetin (50–200 μM) increased ROS generation and induced apoptosis in MCF-7 cells.

Prostate Cancer: Previous studies found that acacetin has anti-tumor effects in that it can induce apoptosis and suppress cell proliferation in gastric carcinoma cells, oral squamous cell carcinoma, and prostate cancer cells.

Evidence Assessment: Although most current research on acacetin remains limited to cellular and animal studies, its diverse bioactivities, accessibility, and safety profile make it a promising candidate for disease prevention and treatment. Acacetin is a potent molecule reported for its strong anti-inflammatory and anti-cancer activity; however, further scientific evidence is essential to validate its potency in disease models associated with inflammation and cancer. No human clinical trials in oncology have been reported to date.

4.3 Neuroprotection

In 6-hydroxydopamine-induced neuronal cells, acacetin exerted neuroprotective effects by inhibiting neurotoxicity and neuronal cell death through the prevention of oxidative stress, apoptotic pathways, and PI3K/Akt, p38 MAPK, JNK, and glycogen synthase kinase-3β (GSK-3β) phosphorylation. Acacetin also inhibits glutamate release, regulates apoptosis in human T-cell leukemia Jurkat cells, and protects against kainic acid-induced neurotoxicity. All evidence in this domain is preclinical.

4.4 Anti-inflammatory and Antinociceptive Activity

Acacetin derived from Agastache mexicana, a Mexican traditional medicinal plant used to reduce pain, anxiety, and insomnia, demonstrated antinociceptive activity in a separate study. Acacetin administered intraperitoneally was assessed using several nociceptive experimental models: the writhing test, the formalin test, and carrageenan paw edema in the thermal plantar tests in mice. Acacetin produced a significant and dose-dependent inhibition of the writhes with an ED₅₀ of 20 mg/kg, and inhibited licking and shaking associated with nociceptive behavior mainly in the inflammatory phase of the formalin test. Systemic administration of acacetin decreased visceral and inflammatory nociception and prevented formalin-induced edema. In the mechanism of the antinociceptive effect, 5-HT1A, GABA/BDZs, and opioid receptors — but not the NO-cGMP-K⁺ channel pathway — appear to be involved. This evidence is from rodent models only.

4.5 Antidiabetic and Metabolic Effects

The flavonoid showed anti-hyperglycemic activity in streptozotocin-induced diabetic mice at oral doses of 3 and 31.6 mg/kg, by decreasing blood glucose levels in healthy and hyperglycemic mice compared to an untreated group. Additionally, acacetin showed stable binding to the active site of aldose reductase, a primary mediator of diabetes-induced oxidative stress in retinopathy. It can interrupt the proton donation mechanism by forming a hydrogen bond with Tyr48 of this enzyme. The study suggested that acacetin, derived from natural sources, could be used as an aldose reductase inhibitor.

As a potent natural antioxidant, acacetin exhibits significant health benefits, including hypoglycemic, anti-inflammatory, and antitumor effects, which may ameliorate conditions such as diabetes, colon cancer, and hypertension. Evidence is based on animal and in vitro models; no human clinical trials have been published.

4.6 Anti-obesity Effects

Acacetin, a flavone isolable from the Saussurea involucrata plant, has anti-tumor and anti-inflammatory properties and has been shown to ameliorate airway hyperresponsiveness in asthmatic mice. One study investigated whether acacetin has anti-adipogenic effects in 3T3-L1 adipocytes and whether it regulates the inflammatory response in adipocytes and macrophages, and also whether acacetin ameliorates lipid accumulation in high-fat diet-induced obese mice. In terms of mechanism, MiR-23b-3p was found to offset the effects of acacetin on body weight, fat percent, inflammatory cytokine levels, and expressions of markers of regulatory T cells (Treg) and T helper 17 cells (Th17). NEU1 was identified as a target of miR-23b-3p, and overexpressed NEU1 reversed effects on reducing Treg cells but increased body weight, fat percent, inflammatory cytokine levels, and percentage of Th17 cells. The findings provide a possible prevention strategy for obesity-induced insulin resistance. All obesity-related evidence is from preclinical (cell and animal) models.

4.7 Hepatoprotection

Intraperitoneal administration of acacetin was found to protect against d-galactosamine/lipopolysaccharide-induced liver injury in mice by suppressing TLR4-signaling and enhancing autophagic flux. It potentially reduced mortality and serum aminotransferase activity at doses of 25, 50, and 100 mg/kg i.p. A water-soluble acacetin prodrug was shown to prevent acetaminophen-induced hepatocyte apoptosis and acute liver injury both in vitro and in vivo, likely through the activation of PPAR-γ signaling and the suppression of endoplasmic reticulum stress. Evidence is preclinical only.

4.8 Antimicrobial Activity

Acacetin has been demonstrated to possess diverse pharmacological effects, comprising antimicrobial, anti-inflammatory, anticancer, antiviral, antioxidant, and anti-infective functions. Literature information reveals that acacetin exhibits pharmacological potential including inhibition of microbial growth, though the breadth of antimicrobial spectrum and clinical relevance have not been defined by human trials.

5. Body Systems and Health Areas Associated with Acacetin

Cardiovascular system: Acacetin has been shown to exert potent cardiovascular protection against multiple pathologies, including arrhythmia, atherosclerosis, hypertension, diabetic cardiomyopathy, myocardial fibrosis and hypertrophy, cardiac ischemia/reperfusion injury, myocardial senescence, and drug-induced cardiotoxicity.
Oncological/cellular protection: In vitro and in vivo studies using diverse tumor models have demonstrated that acacetin modulates oncogenic signaling, suppresses angiogenesis, and induces apoptosis.
Nervous system: Acacetin has demonstrated neuroprotective activities, among its broader pharmacological properties.
Metabolic/endocrine system: Acacetin exhibits hypoglycemic, anti-inflammatory, and antitumor effects which may ameliorate conditions such as diabetes.
Musculoskeletal/immune (anti-inflammatory/anti-arthritic): Acacetin has been studied for rheumatoid and collagen-induced arthritis.
Respiratory system: Acacetin has been investigated for LPS and sepsis-induced lung injury.
Hepatic system: A water-soluble acacetin prodrug was shown to prevent acetaminophen-induced hepatocyte apoptosis and acute liver injury.
Adipose/metabolic: Anti-adipogenic and anti-obesity activity demonstrated in cell and animal models, as described above.

6. Pharmacokinetics

Oral Bioavailability

Acacetin exhibited poor solubility (≤119 ng/mL) and relatively low stability (27.5–62.0% remaining after 24 hours) in pH 7 phosphate buffer and simulated gastrointestinal fluids. A major portion (97.1%) of the initially injected acacetin dose remained unabsorbed in jejunal segments, and the oral bioavailability of acacetin was very low at 2.34% in rats. Despite the low water solubility and poor bioavailability of acacetin, ongoing research has examined prodrug strategies and formulation approaches to address these limitations. Further studies are warranted to resolve the current problems of acacetin, such as poor solubility and rapid metabolism in vivo.

Metabolism

According to a systematic study on the in vitro and in vivo metabolism of acacetin in rats, the dominant phase I metabolism reaction is oxidation, mainly catalyzed by cytochrome P450 (CYP) enzymes. The major phase II metabolites include monoglucuronide and monosulfate, formed mainly by UDP-glucuronosyltransferase (UGT) 1A8 and sulfotransferase (SULT) 1A1, respectively. In rats, 10 phase I metabolites — including apigenin, diosmetin, luteolin, and naringenin — and 21 phase II metabolites were identified in vivo.

Like many xenobiotics, acacetin undergoes metabolism in vivo and can modulate CYP enzyme activity, acting as a potent inhibitor of the CYP1 family. Research indicates that it may also inhibit other CYP450 isoforms, such as CYP2B1, CYP2C9, CYP2C11, CYP2D1, CYP2E1, and CYP3A2. Additionally, acacetin has demonstrated both irreversible and reversible inhibition of CYP3A4.

7. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those reported in the cited preclinical literature. No clinically validated human dosage has been established for acacetin as a dietary supplement or drug candidate.

Animal model (antidiabetic): Oral doses of 3 and 31.6 mg/kg in streptozotocin-induced diabetic mice decreased blood glucose levels.
Animal model (hepatoprotection): Intraperitoneal administration at 25, 50, and 100 mg/kg reduced mortality and serum aminotransferase activity in liver injury models.
Animal model (antinociception): Acacetin produced dose-dependent inhibition of writhing behavior with an ED₅₀ of 20 mg/kg (intraperitoneal).
Animal model (diabetic cardiomyopathy): In vitro, acacetin at 3 μM markedly prevented high glucose-induced changes; in vivo, acacetin prodrug at 10 mg/kg ameliorated cardiac dysfunction and ventricular fibrosis.
Pharmacokinetic interaction study (rats): Twelve male Sprague-Dawley rats received either 50 mg/kg acacetin or vehicle for two weeks, followed by diazepam (10 mg/kg).
In vitro (breast cancer): Acacetin at 50–200 μM increased ROS generation and induced apoptosis in MCF-7 cells.

In order to ensure the safety of acacetin for clinical usage, it is necessary to conduct more investigations, including Phase I clinical trials, for the establishment of safe dosage ranges that balance pharmacological efficacy with potential toxicity. The question of bioavailability in humans has not been addressed and the existing data on toxicity are too sparse to recommend the commercialization of preparations containing acacetin at highly enriched dosages.

8. Safety Considerations and Drug Interactions

General Toxicity Profile

Acacetin is reported for its strong anti-inflammatory and anti-cancer activity; however, further scientific evidence is essential to validate its potency in disease models associated with inflammation and cancer. There is limited information available for toxicity profiling of acacetin; therefore, further studies would aid in establishing this natural flavone as a potent candidate for research studies at the clinical level.

Studies carried out on acacetin suggest that the flavone may be safe to incorporate in commercial nutraceuticals. However, the question of bioavailability in humans has not been addressed and the existing data on toxicity are too sparse to recommend the commercialization of preparations containing acacetin at highly enriched dosages. A critical gap for further research to investigate safety, relying on the use of a variety of animal models, has been identified.

CYP450-Mediated Drug Interactions

The most well-characterized safety concern with acacetin is its potential to alter the metabolism of co-administered pharmaceuticals through inhibition of cytochrome P450 enzymes. Acacetin, alongside chrysin, showed combined irreversible and reversible inhibition of CYP3A4, alerting to possible flavonoid–drug interactions at the level of CYP3A4. Acacetin decreased CYP3A4 enzyme activity by 95%, being the most prominent inhibitor among the flavonoids tested.

A dedicated study examined the interaction with diazepam specifically. The IC₅₀ values for temazepam and nordiazepam in rat liver microsomes were 2.065 μM and 5.2 μM, respectively. In vivo, pretreatment with acacetin increased the area under the curve (AUC) and maximum plasma concentration (C_max) of diazepam, while significantly decreasing its apparent clearance. The AUC values for temazepam and nordiazepam decreased, whereas their clearance values increased significantly. PyMOL simulations indicated that acacetin and diazepam share the same CYP3A4 or CYP2C19 binding pocket, suggesting that acacetin inhibits diazepam metabolism via competitive inhibition.

Acacetin can modulate CYP enzyme activity, acting as a potent inhibitor of the CYP1 family. Research indicates that it may also inhibit CYP2B1, CYP2C9, CYP2C11, CYP2D1, CYP2E1, and CYP3A2. This breadth of CYP isoform inhibition means that acacetin may theoretically increase plasma levels of many co-administered drugs that are substrates of these enzymes, though systematic clinical investigation of this possibility has not been published.

Aromatase Inhibition

Acacetin has a modulating effect on the concentration and activity of aromatase, the enzyme responsible for converting testosterone to estrogen. This effect could have implications for individuals on hormone-dependent therapies or reproductive-axis medications, though the clinical significance in humans at dietary or supplemental exposures has not been studied.

Bioavailability Limitation as a Safety Context

The clinical pharmacological information of acacetin, which is considered an important part of drug development — such as absorption, metabolism, and toxicity — is not sufficient at present. Therefore, all of these need to be further explored and improved upon, so as to confirm the safety and effectiveness of acacetin in the human body. The very low oral bioavailability of ~2.34% reported in rat studies means that systemic exposure from dietary amounts may be substantially lower than doses required to produce the effects observed in in vitro systems, though this also means the drug interaction risks described above may be dose-dependent and context-specific.

Summary of Evidence Strength

Further research, especially specific clinical trials and bioavailability improvement measures, are needed to facilitate the use of acacetin. As of the most recent published reviews (2025), the following characterization applies across domains:

Cardiovascular / anti-arrhythmic: Promising in vitro (human atrial cells) and animal data; no human clinical trials published.
Anticancer: Extensive in vitro evidence across multiple cancer cell lines; animal model data in select tumor types; no human clinical trials.
Anti-inflammatory / antinociceptive: Animal and in vitro data; no human clinical trials.
Antidiabetic / anti-obesity / neuroprotective / hepatoprotective: Preclinical only; no human clinical trials.
Safety / drug interactions: CYP450 inhibition data from in vitro and rat studies; no human pharmacokinetic interaction studies published.

References

Condiciones de Salud

Condiciones de salud que Acazetina puede ayudar a apoyar.

No hay condiciones disponibles.

Sistemas Corporales

Sistemas corporales que Acazetina puede ayudar a apoyar.

No hay sistemas corporales disponibles.